India Pharma Outlook Team | Thursday, 11 June 2026
The global push to develop generic versions of semaglutide is accelerating as patent expiries approach across major markets, intensifying competition in one of the fastest-growing segments of the pharmaceutical industry.
Rising cases of diabetes and obesity worldwide have significantly boosted demand for GLP-1 receptor agonists, turning semaglutide into a multi-billion-dollar therapy category. As a result, pharmaceutical companies are racing to secure early-mover advantage through faster development, regulatory readiness, and manufacturing scale.
Semaglutide has reshaped treatment outcomes in diabetes and weight management, but high costs have limited accessibility in several regions. The expected entry of generics is likely to expand access, particularly in emerging markets where affordability remains a key barrier.
At the same time, developing such complex injectable therapies requires advanced capabilities, pushing companies toward partnerships and shared development models.
Also Read: Are Next-Gen Obesity Drugs Evolving into Multi-Disease Therapies?
Reflecting this broader industry shift, Hyderabad-based Hetero Labs has partnered with European pharmaceutical firm Gedeon Richter to jointly develop, register, and commercialise semaglutide injection globally.
The collaboration is structured as a cost- and profit-sharing model, with clearly defined territorial responsibilities. While Hetero will leverage its strong presence in the US and emerging markets, Richter will drive commercialisation across Europe and Central Asia.
Hetero has already invested in technology setup and initiated registration batch manufacturing, with regulatory filings underway. Submissions in key markets such as the United States and the European Union are planned for 2027, aligning with expected patent expiries.
The agreement also allows for potential future manufacturing in Europe by Richter, which could help diversify supply chains and strengthen regional distribution.
Industry experts note that such collaborations are becoming increasingly common in the race to capture market share in the GLP-1 segment, where speed, scale, and regulatory execution are critical.
For India, the intensifying global race for generic semaglutide presents a significant opportunity to strengthen its pharmaceutical exports and move up the value chain.
Indian companies have traditionally dominated the generics space, but participation in complex therapies like GLP-1 injectables signals a shift toward higher-value innovation-led segments. Early involvement in such markets can enhance India’s competitiveness in regulated markets like the US and Europe.
Additionally, the availability of lower-cost generic semaglutide could improve access to advanced diabetes and obesity treatments domestically, addressing a growing public health challenge.
Also Read: How Semaglutide Works: The Breakthrough Weight-Loss Drug
The growing momentum around generic semaglutide reflects a broader transformation in the pharmaceutical industry, where innovation, affordability, and global collaboration are converging.
As patent expiries unlock new opportunities, partnerships like the Hetero–Richter deal underscore how companies are positioning themselves to compete in a high-growth, high-stakes market that is set to redefine diabetes and obesity care globally.
Hetero Labs is a Hyderabad-based pharmaceutical company specializing in generic drugs, APIs, and biosimilars. With a strong presence in the US and emerging markets, it focuses on complex injectables and affordable therapies across segments including oncology, antivirals, and metabolic diseases.
Gedeon Richter is a Hungary-based global pharmaceutical company with a strong footprint in Europe and Central Asia. It specializes in women’s health, central nervous system, and biosimilar products, supported by robust R&D capabilities and an established commercial distribution network.
.jpg)
